Exelixis Inc. (NASDAQ: EXEL) and its European oncology partner Ipsen have advanced their joint regulatory ambitions in the treatment of advanced neuroendocrine tumors (NETs) with a significant milestone: a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for CABOMETYX® (cabozantinib). This recommendation, announced in June 2025, supports approval of the targeted therapy in adults with previously treated, unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors across the European Union.
The decision builds on CABOMETYX’s growing clinical footprint after the U.S. Food and Drug Administration (FDA) approved its use in this same indication earlier in March 2025. European Commission (EC) ratification is expected within the year, setting the stage for a broader commercial rollout of Exelixis’ flagship oncology product across Europe.
How does the CHMP recommendation impact treatment options for patients with progressing neuroendocrine tumors in Europe?
Neuroendocrine tumors are rare but complex malignancies that originate in hormone-producing cells of the endocrine and nervous systems. Due to their slow-growing nature and often vague symptoms, these tumors frequently go undetected until they reach advanced stages. Treatment options for progressing NETs—particularly after initial systemic therapy—remain limited, especially for non-responsive or non-functional tumor types.
The CHMP’s endorsement applies to adults with unresectable or metastatic, well-differentiated NETs who have experienced disease progression following at least one prior systemic therapy, excluding somatostatin analogs. The EMA’s supportive stance is poised to expand access to a therapy that showed statistically significant efficacy in this patient population during clinical evaluation.
According to Exelixis Chief Medical Officer Dr. Amy Peterson, the treatment’s utility in filling a gap in the post-progression setting has resonated with both clinicians and institutional investors monitoring pipeline diversification in NET therapeutics.
What are the efficacy findings from the CABINET trial that support CABOMETYX use in NET patients?
The CHMP recommendation is underpinned by robust data from CABINET, a randomized, double-blinded, placebo-controlled phase 3 trial conducted by the National Cancer Institute’s Alliance for Clinical Trials in Oncology. The trial enrolled 298 patients in two cohorts—pNET and epNET—and was stopped early after an interim analysis demonstrated superior efficacy for cabozantinib compared to placebo in both groups.
Participants received either a daily 60 mg dose of CABOMETYX or placebo, with progression-free survival (PFS) as the primary endpoint. Secondary endpoints included overall survival and objective response rate, evaluated via RECIST 1.1 criteria. Final results presented at the 2024 European Society for Medical Oncology (ESMO) Congress and published in The New England Journal of Medicine revealed a clear benefit in delaying disease progression, with institutional sentiment suggesting a likely regulatory pathway across global markets.
The CABINET trial required patients to have measurable disease and previous systemic therapy failure, underscoring the therapy’s targeted utility in refractory cases. Notably, tumor sites in epNET patients included gastrointestinal tract, lung, and unknown primaries—adding complexity to treatment responses that cabozantinib appears to address with broad-spectrum tyrosine kinase inhibition.
What is the current regulatory and commercial status of CABOMETYX in the United States and global markets?
CABOMETYX has received multiple global regulatory approvals across solid tumor indications. In the U.S., the therapy is authorized for use as monotherapy in advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC), as well as in combination with nivolumab for frontline RCC treatment. The March 2025 FDA approval extended its label to include adult and pediatric patients (12 years and older) with previously treated, unresectable or metastatic pNET and epNET, aligning the American regulatory landscape with EMA’s evolving stance.
Outside the U.S., Ipsen holds commercial and developmental rights to cabozantinib in all territories excluding Japan, where Takeda Pharmaceutical Company is the licensee. Ipsen’s expansion of the CABOMETYX label in Europe will mark a key inflection point in its commercial strategy to diversify revenue beyond traditional indications such as RCC and HCC.
Analysts tracking the drug’s global sales trajectory anticipate incremental revenue contributions from the NET indication, particularly given the orphan nature of these tumors and the relative lack of treatment alternatives post-somatostatin analog therapy.
How do neuroendocrine tumor survival outcomes vary across anatomical sites and what role could CABOMETYX play?
Neuroendocrine tumors represent a heterogeneous group of malignancies with divergent outcomes based on location and stage. For advanced pancreatic NETs, five-year survival rates hover around 23%, while survival rates for gastrointestinal and lung NETs are markedly higher at 68% and 55%, respectively. However, all forms of metastatic NET ultimately progress, underscoring the importance of novel second-line or later-line treatment options.
CABOMETYX’s multi-targeted mechanism of action—impacting VEGFR, MET, and AXL pathways—enables broad tumor activity across these NET subtypes. Functional NETs, which secrete peptides like serotonin or insulin, may present with hormonal symptoms, while non-functional NETs are primarily diagnosed due to tumor burden. The therapy’s effectiveness across both functional and non-functional disease remains under post-market scrutiny but has been positively received by the medical community due to its trial-confirmed PFS benefits.
What are the safety considerations and risk management strategies for CABOMETYX in NET patients?
As a small-molecule tyrosine kinase inhibitor, CABOMETYX carries class-associated risks, including hypertension, diarrhea, palmar-plantar erythrodysesthesia (PPE), hemorrhage, and thromboembolic events. In the CABINET study, hypertension occurred in 65% of treated patients, with 26% experiencing Grade 3 events.
Exelixis and Ipsen have included detailed risk mitigation strategies in their safety documentation, urging close monitoring of blood pressure, liver enzymes, and signs of gastrointestinal perforation or wound healing impairment. The drug is contraindicated in patients with recent hemorrhagic events and requires dose modifications for adverse events such as proteinuria or thyroid dysfunction.
While institutional sentiment supports the benefit-risk ratio of CABOMETYX in advanced NETs, long-term pharmacovigilance remains crucial, particularly in pediatric populations and patients with hepatic impairment. European prescribers are expected to adopt a similar safety framework post-approval, modeled on U.S. guidelines.
How do institutional investors and analysts view the market potential for CABOMETYX in rare oncology indications?
CABOMETYX has long been viewed as a foundational product in Exelixis’ oncology portfolio, with revenue exceeding USD 1 billion annually. Institutional investors see the expansion into rare tumors like NETs as a strategic diversification move that strengthens the product’s lifecycle and offsets competitive pressures in mature indications.
Ipsen’s role in European commercialization further de-risks the program, enabling Exelixis to focus on pipeline development while benefiting from royalty streams. Analysts expect additional filings for other rare or resistant tumor types, bolstered by ongoing research collaborations with the NCI and international academic institutions.
With EMA approval likely following CHMP’s favorable opinion, investors anticipate meaningful top-line growth in 2026 from expanded European access, particularly in high-need therapeutic niches.
What is the future outlook for CABOMETYX in Europe following CHMP’s recommendation?
With the CHMP opinion in hand, the European Commission is expected to issue a final decision on CABOMETYX for previously treated pNET and epNET within the second half of 2025. If approved, the therapy will be positioned to fill a critical treatment gap for European patients with refractory or relapsed neuroendocrine tumors.
Ipsen is expected to lead commercialization efforts across EU member states, leveraging its existing oncology sales infrastructure. The rollout will likely begin in high-uptake markets such as Germany, France, and Italy, where clinician awareness of CABOMETYX in RCC and HCC could accelerate adoption in NETs.
Looking forward, analysts believe the therapy could eventually expand into combination regimens or be evaluated in earlier treatment settings as real-world data accumulate. With CABINET trial data providing a strong foundation and regulatory bodies responding positively, CABOMETYX is well-positioned to become a cornerstone in NET management within the European oncology landscape.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
